Semaglutide pills help high-risk patients lower their risk of a heart attack or stroke

Oral semaglutide is associated with a reduced risk of heart attack, stroke or cardiovascular death for patients with type 2 diabetes, according to new findings published in JAMA Cardiology.[1] This includes both first and subsequent events. 

Back in 2025, the SOUL clinical trial found that oral semaglutide—sold by Novo Nordisk under the brand names Wegovy and Ozempic—could help patients with type 2 diabetes lower their risk of major adverse cardiovascular events.[2] However, that study only focused on the first occurrence of an adverse event, not subsequent events. This updated analysis explored the same data, but looked at both first and subsequent major adverse cardiovascular events. 

“Total event analyses, assessing both first and subsequent events, can contribute to a better understanding of the impact of interventions on the total burden of disease,” wrote first author Nikolaus Marx, MD, a researcher with RWTH Aachen University in Germany, and colleagues.

Marx et al. evaluated data from nearly 10,000 patients with a mean age of 66 years old. All patients had type 2 diabetes in addition to atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Patients were randomized to either receive oral semaglutide or a placebo. The primary endpoint was a composite of cardiovascular death, first or subsequent nonfatal myocardial infarction and first or subsequent nonfatal stroke. 

Overall, the patients receiving oral semaglutide experienced a total of 683 major adverse cardiovascular events. This included 579 first events and 104 subsequent events. The patients given a placebo, meanwhile, experienced a total of 791 major adverse cardiovascular events. This included 668 first events and 123 subsequent events.

Subscribe to Cardiovascular Business News

When noncardiovascular deaths were also included, oral semaglutide was still linked to a reduced risk—910 total events for the oral semaglutide patients and 1,048 total events for the placebo patients. 

“The assessment of total (first and subsequent) events deepens our understanding of the disease burden and risk in individuals with T2D and ASCVD and/or CKD,” the authors wrote, adding that these subsequent events represent “clinically relevant information not captured by time-to-first-event analyses.” 

The group concluded with a big-picture look at the use of oral semaglutide to treat a wide range of patients.

“These data add to previous evidence of the ability of oral semaglutide to reduce cardiovascular outcome events and suggest a benefit on the total burden of cardiolovascular morbidity and mortality in this high-risk population,” the authors wrote.

Novo Nordisk, the manufacturer of oral semaglutide, funded the original SOUL trial as well as this follow-up analysis.

Click here to read the full study in JAMA Cardiology.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News